Physician profile
Jack D Gray
NPI 1639405061
$1,253.78
in general payments reported to CMS, 2019-2025
11 companies · $832 in 2025
The $832 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9.33 · 2022: $183 · 2023: $196 · 2024: $33.10 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876 · Travel and Lodging: $140 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.83 |
| Travel and Lodging | $140.40 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $427.61 | 2025 | Intellis Adaptivestim |
| Gilead Sciences, INC. | $125.00 | 2025 | Livdelzi |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Kerecis Limited | $110.76 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Biohaven Pharmaceutical Holding Company Ltd. | $107.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $82.80 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.26 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $76.05 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $75.70 | 2023-2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $33.10 | 2024 | |
| Genentech USA, INC. | $9.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.